OBJECTIVE: Pathologic changes in varicella-zoster virus (VZV)-infected arteries include inflammation, thickened intima, and paucity of smooth muscle cells. Since no criteria have been established for early vs late VZV vasculopathy, we examined inflammatory cells and their distribution in 6 normal arteries, and 2 VZV-infected arteries 3 days after onset of disease (early) and 10 months after protracted neurologic disease (late). METHODS: VZV-infected temporal artery obtained 3 days after onset of ischemic optic neuropathy from an 80-year-old man, VZV-infected middle cerebral artery (MCA) obtained 10 months after protracted disease from a 73-year-old man, and 5 MCAs and 1 temporal artery from normal subjects, age 22-60 years, were examined histologically and immunohistochemically using antibodies against VZV and inflammatory cell subsets. RESULTS: In both early and late VZV vasculopathy, T cells, activated macrophages, and rare B cells were found in adventitia and intima. In adventitia of early VZV vasculopathy, neutrophils and VZV antigen were abundant and a thickened intima was associated with inflammatory cells in vaso vasorum vessels. In media of late VZV vasculopathy, viral antigen, but not leukocytes, was found. VZV was not seen in inflammatory cells. Inflammatory cells were absent in control arteries. CONCLUSIONS: Both VZV and neutrophils exclusively in adventitia in early VZV vasculopathy indicate that disease begins there. Late VZV vasculopathy is distinguished by viral antigen without inflammation in media, revealing a human virus in an immunoprivileged arterial media. Association of thickened intima and inflammation in vaso vasorum vessels in early VZV vasculopathy support the role of virus-induced inflammation in vessel wall remodeling.
OBJECTIVE: Pathologic changes in varicella-zoster virus (VZV)-infected arteries include inflammation, thickened intima, and paucity of smooth muscle cells. Since no criteria have been established for early vs late VZV vasculopathy, we examined inflammatory cells and their distribution in 6 normal arteries, and 2 VZV-infected arteries 3 days after onset of disease (early) and 10 months after protracted neurologic disease (late). METHODS:VZV-infected temporal artery obtained 3 days after onset of ischemic optic neuropathy from an 80-year-old man, VZV-infected middle cerebral artery (MCA) obtained 10 months after protracted disease from a 73-year-old man, and 5 MCAs and 1 temporal artery from normal subjects, age 22-60 years, were examined histologically and immunohistochemically using antibodies against VZV and inflammatory cell subsets. RESULTS: In both early and late VZV vasculopathy, T cells, activated macrophages, and rare B cells were found in adventitia and intima. In adventitia of early VZV vasculopathy, neutrophils and VZV antigen were abundant and a thickened intima was associated with inflammatory cells in vaso vasorum vessels. In media of late VZV vasculopathy, viral antigen, but not leukocytes, was found. VZV was not seen in inflammatory cells. Inflammatory cells were absent in control arteries. CONCLUSIONS: Both VZV and neutrophils exclusively in adventitia in early VZV vasculopathy indicate that disease begins there. Late VZV vasculopathy is distinguished by viral antigen without inflammation in media, revealing a human virus in an immunoprivileged arterial media. Association of thickened intima and inflammation in vaso vasorum vessels in early VZV vasculopathy support the role of virus-induced inflammation in vessel wall remodeling.
Authors: Aaron Haug; Ravi Mahalingam; Randall J Cohrs; D Scott Schmid; John R Corboy; Don Gilden Journal: J Neurol Sci Date: 2010-02-19 Impact factor: 3.181
Authors: Maria G Frid; Jacqueline A Brunetti; Danielle L Burke; Todd C Carpenter; Neil J Davie; John T Reeves; Mark T Roedersheimer; Nico van Rooijen; Kurt R Stenmark Journal: Am J Pathol Date: 2006-02 Impact factor: 4.307
Authors: Richard Salazar; Andrew N Russman; Maria A Nagel; Randall J Cohrs; Ravi Mahalingam; D Scott Schmid; Bette K Kleinschmidt-DeMasters; Eve M VanEgmond; Don Gilden Journal: Arch Neurol Date: 2011-04
Authors: D H Gilden; B K Kleinschmidt-DeMasters; M Wellish; E T Hedley-Whyte; B Rentier; R Mahalingam Journal: Neurology Date: 1996-12 Impact factor: 9.910
Authors: F Perros; P Dorfmüller; R Souza; I Durand-Gasselin; V Godot; F Capel; S Adnot; S Eddahibi; M Mazmanian; E Fadel; P Hervé; G Simonneau; D Emilie; M Humbert Journal: Eur Respir J Date: 2006-12-20 Impact factor: 16.671
Authors: Dallas Jones; Anna Blackmon; C Preston Neff; Brent E Palmer; Don Gilden; Hussain Badani; Maria A Nagel Journal: J Virol Date: 2016-11-14 Impact factor: 5.103
Authors: Maria A Nagel; Alexander Choe; Nelly Khmeleva; Lindsey Overton; April Rempel; Ann Wyborny; Igor Traktinskiy; Don Gilden Journal: J Neurovirol Date: 2013-03-01 Impact factor: 2.643
Authors: Samuel B Snider; Claire S Jacobs; Patricia S Scripko; Joshua P Klein; Jennifer L Lyons Journal: J Neurovirol Date: 2014-05-08 Impact factor: 2.643
Authors: Anna M Blackmon; Christina N Como; Andrew N Bubak; Teresa Mescher; Dallas Jones; Maria A Nagel Journal: J Infect Dis Date: 2019-09-26 Impact factor: 5.226
Authors: Andrew N Bubak; Vicki Traina-Dorge; Christina N Como; Brittany Feia; Catherine M Pearce; Laura Doyle-Meyers; Arpita Das; Jayme Looper; Ravi Mahalingam; Maria A Nagel Journal: J Neurovirol Date: 2020-09-22 Impact factor: 2.643